Basel, July 1, 2023 – Sandoz, a global leader in generic pharmaceuticals and biosimilars, today announced that the citrate-free high-concentration formulation (HCF) of its biosimilar Hyrimoz ® ...

(RTTNews) - Sandoz said that the citrate-free high-concentration formulation or HCF of its biosimilar Hyrimoz (adalimumab-adaz) injection will be available in the United States starting July 1.

FDA approval of generic pharmaceutical maker Sandoz’s Hyrimoz injection, a biosimilar for Humira, has the potential to “to expand access for millions,” according to a March 21 news release. The ...

Sandoz has obtained the Food and Drug Administration’s blessing for a citrate-free high-concentration formulation of its biosimilar Hyrimoz (adalimumab-adaz) injection. The adalimumab citrate-free HCF ...

The biosimilar Hyrimoz showed similar flare rates to Humira, but 25% of patients experienced adverse events, mainly injection site reactions. Injection pain, linked to Hyrimoz's citrate content and ...

Sandoz, a global leader in generic pharmaceuticals and biosimilars, announced that the citrate-free high-concentration formulation (HCF) of its biosimilar Hyrimoz (adalimumab-adaz) injection will be ...

(RTTNews) - Sandoz announced the European Medicines Agency has accepted the application for high concentration formulation 100 mg/mL of its biosimilar Hyrimoz for regulatory review. The company noted ...

BOUCHERVILLE, Quebec, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Sandoz Canada Inc. announced today that Health Canada has authorized Hyrimoz ® (adalimumab injection, reference biologic drug: Humira ®) on ...

Novartis’ Sandoz is pushing to wipe out an advantage AbbVie’s Humira enjoys over its biosimilar rival in the EU, securing regulatory acceptance of a filing for a high-concentration formulation of the ...

Hyrimoz® (adalimumab-adaz) high-concentration formulation (HCF) biosimilar offers US patients reduced injection volume in citrate-free formulation As one of the only adalimumab HCF biosimilars ...